Navigation Links
MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
Date:1/30/2008

GERMANTOWN, Md., Jan. 30 /PRNewswire-FirstCall/ -- MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK), a pharmaceutical company focused on developing and commercializing novel anti-infective products, today announced that it has closed its previously announced private placement of common stock and warrants, resulting in the receipt of $21 million in gross proceeds.

The Company intends to use the proceeds from the financing to support the manufacture of MOXATAG(TM), its once-daily amoxicillin product, and for working capital and general corporate purposes.

The shares sold in the private placement and the shares issuable upon the exercise of the related warrants have not been registered under the Securities Act of 1933, as amended, or state securities laws, and may not be offered or sold in the United States without being registered with the Securities and Exchange Commission ("SEC") or through an applicable exemption from SEC registration requirements. The shares and warrants were offered and sold only to institutional and accredited investors. The Company has agreed to file a registration statement with the SEC covering the resale of the common stock issued in the private placement and issuable upon the exercise of the warrants.

This news release is not an offer to sell or the solicitation of an offer to buy the shares of the Company.

About MiddleBrook Pharmaceuticals:

MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) is a pharmaceutical company focused on the development and commercial
'/>"/>

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sagent Pharmaceuticals, Inc. to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
2. Access Pharmaceuticals Announces $2.7 Million New Equity
3. Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award
4. Alexion Pharmaceuticals Invites You to Participate in its Fourth Quarter and Full Year 2007 Results Conference Call and Web Cast
5. Cylene Pharmaceuticals Appoints Kenna Anderes, Ph.D. as Vice President of Cancer Biology
6. Onyx Pharmaceuticals to Present at Wachovia Healthcare Conference
7. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
8. Angiotech Pharmaceuticals, Inc. - Notice of Conference Call and Webcast
9. VIA Pharmaceuticals Names Rebecca Taub Senior Vice President of Research and Development
10. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
11. Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... DIEGO , July 24, 2014   ... announced today the appointment of Adam Simpson ... Cypher Genomics provides rapid and comprehensive annotation and ... and clinical reporting. "Cypher,s technology has ... improve healthcare by enhancing diagnostic accuracy, optimizing therapeutic ...
(Date:7/23/2014)... YORK , July 24, 2014 ... Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX First ... "Immune" or "the Company"), announced a collaboration to ... pemphigoid last night at an event attended by ... interested parties. Lyfebulb is a health and wellness ...
(Date:7/23/2014)... worldwide conservation efforts have made great strides in saving ... China, there are over 65 giant panda reserves that ... despite these efforts, just 1596 pandas remain in the ... zoos hope to save the panda by improving genetic ... the wild. Just how are these high-profile programs doing ...
(Date:7/23/2014)... -- Think Drinks are a neuroscience-backed drink regimen developed ... are the first functional focus beverage to give users ... to the temporary fix associated with energy drinks. truBrain ... 2014, with hopes to raise $50,000 over the course ... http://photos.prnewswire.com/prnh/20140723/129697 Think Drinks were designed ...
Breaking Biology Technology:Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 2Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 3Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 2Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 3Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 4Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 5truBrain Neuroscientists To Launch More Effective, Healthier Alternative To Energy Drinks On Indiegogo 2
... Fund More Than Doubles Assets Under Management, UTRECHT, ... growing European venture capital firm, today announced,the closing of ... Gilde,Healthcare II (GHC II). The new fund, which is ... funds raised to invest in European,healthcare opportunities. GHC II ...
... Emerging Nanotechnologies will host the U.S. launch of ... Responsible Nanotechnology aimed principally at businesses and research ... Society and the United Kingdom government-sponsored Nanotechnology Knowledge ... Association, Insight Investment. , The event ...
... Genmab Antibody,Summary: Genmab,s Partner Roche has Filed a CTA With the ... ... COPENHAGEN, October 2 Genmab A/S (OMX: GEN),announced today that ... British Medicines and Healthcare products,Regulatory Agency (MHRA) for a Genmab antibody ...
Cached Biology Technology:Gilde Healthcare Partners Closes EUR 150 Million European Healthcare Venture Fund 2A new 'responsible nanocode' for business 2Genmab A/S - Company Announcement 2
(Date:7/23/2014)... risk warning for Yellowknife and surrounding area because of ... In the image taken by the Aqua satellite, ... Fire is an obvious health hazard, but the ... obvious and its effects are insidious. , The smoke ... structure, tires, waste or wood burning) is a mixture ...
(Date:7/23/2014)... entire country in its grip is affecting more than the ... the proliferation of a heat-loving amoeba commonly found in warm ... the drought has made warmer than usual this year. , ... by this parasite after swimming in several area lakes. The ... and travels to the brain. Nose plugs can lower the ...
(Date:7/23/2014)... This news release is available in German . ... shape and stability to cells, drive metabolic processes and ... into complex three-dimensional shapes. Scientists at the Max Planck ... that proteins can be constructed of similar amino acid ... suggests that the proteins that exist today arose from ...
Breaking Biology News(10 mins):Diseases of another kind 2Protein evolution follows a modular principle 2
... has destroyed 17 percent of the native vegetation in ... new study published by Conservation International sounds an alarm ... Continued deforestation at the current rate would cause all ... years, according to CI researchers in Brazil. , Overall, ...
... It's one of those unavoidable facts of life -- ... internal temperatures cause only temporary discomfort, but in some ... , These convulsions are "scary and very upsetting to ... chair of Neurology. They've also been something of an ...
... shows that robot assisted knee surgery is significantly ... of surgeons tested whether Acrobot, a robotic assistant, ... knee replacement. Acrobot works by helping the surgeon ... the existing bones. , The surgeons looked at ...
Cached Biology News:Report shows deforestation threatens Brazil's Pantanal 2Molecular mechanism may explain how fevers spark seizures 2Molecular mechanism may explain how fevers spark seizures 3Robot assisted surgery more accurate than conventional surgery 2
Polyclonal Antibody to Coronin / CORO1C This antibody was developed against synthetic peptides corresponding to amino acids 407-420 of human CORO1C....
Peptide-affinity Purified Polyclonal Antibody to Retinoic Acid-Induced 3 (RAI3/RAIG1)...
...
Co-precipitant is free of background polynucleotides,Dnases,Rnases, proteases. 20mg/ml...
Biology Products: